[Video] Measuring the development of Alzheimer’s disease

Posted on 27 May 2015 in Clinical Trials / Healthcare / Research

Professor Barbara Sahakian explains the success of the Cantab PAL in moving the field forward for Alzheimer's disease, opening the possibility for early detection and for allowing easier trial enrolment.  

Barbara Sahakian DSc FMedSci is Professor of Clinical Neuropsychology at the Department of Psychiatry and Medical Research Council (MRC)/Wellcome Trust Behavioural and Clinical Neuroscience Institute, University of Cambridge as well as being an Honorary Clinical Psychologist at Addenbrooke's Hospital, Cambridge. She has an international reputation in the fields of cognitive psychopharmacology, neuroethics, neuropsychology, neuropsychiatry and neuroimaging.

Professor Sahakian is a Fellow of Clare Hall, Cambridge and currently President of the International Neuroethics Society (INS), of which she is a founder member. She was previously President of the British Association for Psychopharmacology (BAP).